Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 醫學院
  3. 分子醫學研究所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52259
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor黃璉華(Lian-Hua Huang)
dc.contributor.authorYu-Ju Linen
dc.contributor.author林育如zh_TW
dc.date.accessioned2021-06-15T16:10:28Z-
dc.date.available2020-09-25
dc.date.copyright2015-09-25
dc.date.issued2015
dc.date.submitted2015-08-18
dc.identifier.citation參考文獻
中文文獻
任怡慧(2006)•以唐氏症血清篩檢法作為偵測孕婦中胎兒染色體異常之探討(碩
士論文).基隆:國立臺灣海洋大學食品科學研究所。
行政院國民健康局(2011).第十次家庭與生育力調查報告.取自http://www.bhp.doh.gov.tw/bhpnet/portal/Them_Show.aspx?Subject=200712270003&Class=2&No=200801180003。
吳筱郁(2014).羊膜穿刺檢查於偵測胎兒染色體異常之重要性探討(未發表的
碩士論文).臺北:大同大學生物工程學研究所。
宋克芳(2005).「計畫外出生先天缺陷兒」之民事損害賠償責任研究(碩士論
文).臺南:國立成功大學法律學研究所。
李妙虹(2003).戰後臺灣婦女的社會地位(1970-2000)(碩士論文).台中:國立中興大學歷史學研究所。
李耀泰、陳福民、郭宗正(2012).葉酸與懷孕.當代醫學,39(5),393-396。
周承珍、李從業、施富金 (2001)•母血篩檢唐氏症陽性孕婦面對羊膜穿刺術的
決策過程•護理研究,9(1),15-27。
林秀娟(1994).唐氏症.中兒醫誌,35(A),28-31。
林家君(2004).第一孕期胎兒頸部透明帶厚度測量與第二孕期生化試驗於偵測
胎兒染色體異常(碩士論文).臺中:國立中興大學生命科學系研究所。
林稚琇(2008).孕婦接受羊膜穿刺檢查動機與遺傳諮詢成效之探討(碩士論文).臺北:國立臺灣大學分子醫學研究所。
林欣頤(2010)•計畫外生育民事賠償責任研析與實證研究(碩士論文).新竹:國立交通大學科技法律研究所。
柯滄銘(1991)•產前遺傳診斷的新發展•當代醫學,208,163-164。
徐金梅(2005)•胎兒染色體異常的婦女於第二孕期接受終止妊娠之生活經驗(未
發表的碩士論文)•臺北:國立臺灣大學護理學研究所。
高嘉霙、郭素珍(2012).唐氏症篩檢孕婦之護理.助產雜誌,54,10-17。
郭義興(2003).台灣母血唐氏症篩檢對唐氏症出生趨勢之影響(碩士論文).臺北:國立臺灣大學分子醫學研究所。
陳冠如、蕭寧馨、林璧鳳(2006).台北地區醫院產檢孕婦的葉酸營養狀況.臺
灣營養學會雜誌,31(1),8-16。
陳素珍、黃璉華、陳品玲、陳家玉、蘇本華(2006)•護理人員對遺傳性疾病之知識、態度與教育需求之探討•臺灣醫學,10(6),675-687。
陳伊莉(2012)•台灣母血唐氏症篩檢對唐氏症出生趨勢之影響(碩士論文).臺北:國立臺灣大學分子醫學研究所。
陳惠瑩(2013)•影響懷孕婦女對不同唐氏症篩檢選擇的因素與後續遺傳諮詢需
求(碩士論文).臺北:國立臺灣大學分子醫學研究所。
喻永生(1993).唐氏症候群.國防醫學,16(1),35-45。
黃璉華(1994).養育唐氏症兒對家庭的衝擊.護理研究,2(3),253 - 262。
黃璉華(1995).生育先天性缺陷兒對家庭的影響.中華公共衛生雜誌,14(4),
299-313。
黃璉華(2001).遺傳諮詢對減緩接受羊膜穿刺孕婦焦慮程度之成效.公共衛生, 27(4),301-314。
黃美智、吳翠雲、林秀娟(1996).孕婦接受台南市某二區域醫院羊膜腔穿刺術
諮詢前後之認知與擔憂研究.中華公共衛生雜誌,12(6),546-555。
黃怡瑾、胡淑貞、王瑤華、林秀娟(2005).基因科技發展下的生育與醫病互動.
台灣醫學人文學刊,6(1-2),87-111。
黃柏青、邱建勳(2010)•產前唐氏症篩檢•當代醫學,442,614-618。
黃瑜琛(2004).初次接受產前母血唐氏症篩檢陽性反應婦女之懷孕生產經驗(碩士論文).臺南:國立成功大學護理學系。
黃楷婷(2013).實施罕見疾病基因檢測之必要性及倫理指導原則的探討(碩士論文).臺中:中興大學法律學系科技法律研究所。
劉恬伃(2008).越南籍及台籍配偶於母血篩檢決定過程中的知情選擇(未
發表的碩士論文).臺南:國立成功大學護理研究所。
蔡甫昌、張至寧、楊智超、胡務亮(2008).臺灣遺傳檢驗與咨詢施行之現況分析與倫理反省.醫學教育,12(3),176-195。
蔡甫昌、鍾珞筠、簡穎秀、胡務亮(2013)•大規模人口遺傳疾病篩檢之倫理議
題與國家政策•臺灣醫學,17(1),58-69。
蔣欣欣、喻永生、余玉眉(2005).剖析產前遺傳檢測之諮詢與倫理議題.中華
心理衛生學刊,18(1),65-86。
蔣欣欣(2010)•生物醫學化中護理照顧之反思-以母血唐氏症篩檢為例•護理
雜誌,57(6),18-23。
衛生福利部國民健康署(2014).中華民國102年出生通報統計年報.取自http://www.hpa.gov.tw/bhpnet/Portal/File/ThemeDocFile/201411070707245382/102%E5%B9%B4%E5%87%BA%E7%94%9F%E9%80%9A%E5%A0%B1%E5%B9%B4%E5%A0%B1(%E5%9C%8B%E6%B0%91%E5%81%A5%E5%BA%B7%E7%BD%B2%E7%B7%A8%E5%8D%B0).pdf
鄭博仁、林俊宏、李昭男(1985).妊娠早期絨毛膜活體檢查.當代醫學,137, 200-203。
戴志宇(2012)•探討病患信任的前置因子與影響(碩士論文)•桃園:元智大
學資訊管理學系研究所。
薛夙君(1997)•唐氏症產前母血血清篩檢行為之相關因素探討(碩士論文).高雄:高雄醫學大學公共衛生學研究所。
謝豐舟(1994)•先天性畸形-超音波在胎兒先天性畸形之診斷•中華民國小兒
科醫學會雜誌,35(1),32-32。
關惠鍾(2011)•懷孕狀態與兩階段產前遺傳檢查的個人知識、知識需求、不確
定感及接受度之關係(碩士論文).臺北:國立臺灣大學分子醫學研究所。







英文文獻
Antsaklis, A. J., Papantoniou, N. E., Daskalakis, G. J., Mesogitis, S. A., Kitmirides, S. J., & Michalas, S. S. (2001). False positive serum biochemical screening and subsequent fetal loss in women less than 35 years of age. An International Journal of Obstetrics & Gynaecology, 108(6), 589-593.
Browner, C. H., Preloran, H., & Cox, S. J. (1999). Ethnicity, bioethics, and prenatal diagnosis: the amniocentesis decisions of Mexican-origin women and their partners. American Journal of Public Health, 89(11), 1658-1666.
Brambati, B., Macintosh, M. C., Teisner, B., Maguiness, S., Shrimanker, K., Lanzani, A., … Grudzinskas, J. G. (1993). Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. An International Journal of Obstetrics and Gynaecology, 100(4), 324-326.
Beard, J. L. (2000). Effectiveness and strategies of iron supplementation during pregnancy. American Journal of Clinical Nutrition, 71(5), 1288S–1294S.
Bernhardt, B. A., Geller, G., Doksum, T., Larson, S. M., Roter, D., & Holtzman, N. A.
(1998). Prenatal genetic testing:content of discussion between obstetric providers and pregnant women. Obstetrics & Gynecology, 91(5Pt 1), 648-655,.
Bogart, M. H., Pandian, M. R., & Jones, O. W. (1987). Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenatal Diagnosis, 7(9), 623-630.
Chilaka, V. N., Konje, J. C., Stewart, C. R., Narayan, H., & Taylor, D. J. (2001).
Knowledge of Down syndrome in pregnant women from different ethic group. Prenatal Diagnosis, 21(3), 159-164.
Cicero, S.1., Curcio, P., Papageorghiou, A., Sonek, J., & Nicolaides, K. ( 2001). Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet, 358(9294), 1665-1667.
Canick, J. A., Knight, G. J., Palomaki, G. E., Haddow, J.E., Cuckle, H. S., & Wald, N. J. (1988). Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. An International Journal of Obstetrics & Gynaecology, 95(4), 330-333.
Chao, A. S., Chung, C.L., Wu, C.D., Chang, S. D., Cheng, P. J., Lin, Y. T., & Soong, Y. K. (1999). Second trimester maternal serum screening using alpha fetoprotein, free beta human chorionic gonadotropin and maternal age specific risk: result of chromosomal abnormalities detected in screen positive for Down syndrome in an Asian population. Acta Obstetricia et Gynecologica Scandinavica, 78(5), 393-397.
Cuckle, H. S., Wald, N. J., & Lindenbaum, R. H. (1984). Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome.
Lancet, 1(8383), 926-929.
Dastgiri, S. 1., Stone, D., H, Le-Ha, C., & Gilmour, W. H. (2002). Prevalence and secular trend of congenital anomalies in Glasgow, UK. Archives Of Disease In Childhood, 86(4), 257-263.
Down, J. L. H., (1867). Observations on an Ethnic Classification of Idiots. The British Journal of Psychiatry, 13 (61), 121-123.
Dahl, K., Kesmodel, U., Hvidman, L., & Olesen, F. (2006). Informed consent: attitudes, knowledge and information concerning prenatal examinations. Acta Obstetricia et Gynecologica Scandinavica, 85(12), 1414-1419.
Favre, R., Moutel, G., Duchange, N., Vayssière, C., Kohler, M., Bouffet, N., …Nisand, I.(2008) . What about informed consent in first-trimester ultrasound screening for Down syndrome?. Fetal Diagnosis and Therapy, 23(3), 173-184.
Goodwin, B. A., & Huether, C. A. (1987). Revised estimates and projections of Down syndrome births in the United States, and the effects of prenatal diagnosis utilization, 1970-2002. Prenatal Diagnosis, 7(4), 261-271.
Gourounti, K., & Sandall, J. (2008). Do pregnant women in Greece make informed choices about antenatal screening for Down's syndrome? A questionnaire survey. Midwifery, 24(2), 153-162.
Hall, S., Bobrow, M., & Marteau, T. M. (2000). Psychological consequences for parents of false negative results on prenatal screening for Down’s syndrome: Retrospective interview study. British Medical Journal, 320(7232), 407 -412.
Halliday, J. L., Watson, L. F., Lumley, J., Danks, D. M., & Sheffield, L. J. (1995).
New estimates of Down syndrome risks at chorionic villus sampling, amniocentesis, and livebirth in women of advanced maternal age from a uniquely defined population. Prenatal Diagnosis, 15(5), 455-465.
Hibbard, E. D., & Smithells, R.W. (1965). Folic acid metabolism and human embryopathy. Lancet, 285, 1254.
Hofman, K. J., Tambor, E. S., Chase, G. A., Geller, G., Faden, R. R., & Holtzman, N. A. (1993). Physicians’ knowledge of genetics and genetic tests. Academic Emergency Medicine, 68(8), 625-632.
Kuller, J. A., & Laifer, S. A. (1996). Issues associated with prenatal testing for fetal abnormalities. American Family Physician, 53(8), 2435-2440.
Knutzen, D. M., Stoll, K. A., McClellan, M. W., Deering, S. H., & Foglia, L. M. (2013). Improving knowledge about prenatal screening options: can group education make a difference?. The Journal of Maternal-Fetal & Neonatal Medicin, 26(18), 1799-1803.
Kuppermann, M. D., Feeny, E., Gates, S., Posner, B., & Blumberg, A. E. (1996). Preferences of women facing a prenatal diagnostic choice: implications for genetic testing guidelines. Medical Decision Making, 16, 466.
Lejeune, J., Gautier, M., & Turpin, R. (1959). Study of somatic chromosomes from 9 mongoloid children. C R Hebd Seances Acad Sci, 248(11), 1721-1722.
Leonard, H., & Wen, X. (2002). The epidemiology of mental retardation: Challenges and opportunities in the new millennium. Mental Retardation and Developmental Disabilities Research Reviews, 8(3), 117-134.
Lin, S. J., Huang, M. C., Chen, S. H., Tsai, C. J., & Shu, S. F. (1995). A follow-up study of genetic counseling in Down syndrome. Acta Paediatrica Taiwanica, 36(3), 192-196.
Malone, F. D., Canick, J. A., Ball, R. H., Nyberg, D. A., Comstock, C. H., Bukowski, R., …D'Alton, M. E. (2005). First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome. The New England Journal of Medicine, 353(19), 2001-2011.
Mosley, B. S., Hobbs, C. A., Flowers, B. S., Smith, V., & Robbins, J.M. (2007).
Folic acid and the decline in neural tube defects in Arkansas. The Journal of the Arkansas Medical Society, 103(10), 247-250.
Marteau, T. M., Cook, R., Kidd, J., Michie, S., Johnston, M., Slack, J., & Shaw, R. W.
(1992). The psychological effects of false-positive results in prenatal screening for fetal abnormality: A prospective study. Prenatal Diagnosis, 12(3), 205-214.
Mulvey, S. 1., & Wallace, E. M. (2000). Women's knowledge of and attitudes to first and second trimester screening for Down's syndrome. An International Journal of Obstetrics & Gynaecology, 107(10), 1302-1305.
Marteau, T. M. (1993 ). Psychological consequences of screening for Down’s syndrome. British Medical Journal, 307(6897), 146-147.
Merkatz, I. R., Nitowsky, H. M., Macri, J. N., & Johnson, W. E. (1984). An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. American Journal of Obstetrics and Gynecology,
148(7), 886-894.
Macri, J.N., Kasturi, R. V., Krantz, D. A., Cook, E. J., Moore, N.D., Young, J. A., … Larsen, J. W. Jr. (1990). Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin. American Journal of Obstetrics and Gynecology, 163(4 Pt 1), 1248-1253.
Mulvey, S., & Wallace, E. M. (2000). Women's knowledge of and attitudes to first and second trimester screening for Down's syndrome. An International Journal of Obstetrics & Gynaecology, 107(10):1302-1305.
Manopunya, M., & Wanapirak, C. (2008). Thai pregnant women knowledge and attitudes about maternal serum screening for Down’s syndrome. Thai Journal of Obstetrics and Gynaecology, 16(3), 163-172.
Niebuhr, E. (1974). Down's syndrome. Human Genetik, 21(1), 99–101.
Nicolaides, K. H. (2004). Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. American Journal of Obstetrics & Gynecology, 191(1), 45–67.
Nicolaides, K. H., Azar, G., Byrne, D., Mansur, C., & Marks, K. (1992). Fetal nuchal translucency:ultrasound screening for fetal chromosomal defects in first trimester of pregnancy. British Medical Journal, 304 (6831), 867-869.
Penrose, L. S. (1933). The relative effects of paternal and maternal age in mongolism. Journal of Genetics, 27(2), 219-224.
Pruksanusak, N., Suwanrath, C., Kor-Anantakul, O., Prasartwanakit, V., Leetanaporn, R., Suntharasaj, T., & Hanprasertpong, T. (2009). A survey of the knowledge and attitudes of pregnant Thai women towards Down syndrome screening. The Journal of Obstetrics and Gynaecology Research, 35(5):876-881.
Press, N. & Clayton, E. W. (2000). Genetics and Public Health: Informed Consent Beyond the Clinical Encounter. In Muin J. Khoury ,Wylie Burke & Elizabeth J. Thomson (Eds.) Genetics and public health in the 21st Century, 505-526. New York: Oxford University Press Inc.
Papantoniou, N. E., Daskalakis, G. J., Tziotis, J. G., Kitmirides, S. J., Mesogitis, S. A., & Antsaklis, A. J. (2001). Risk factors predisposing to fetal loss following a second trimester amniocentesis. An International Journal of Obstetrics & Gynaecology, 108(10), 1053-1056.
Palomaki, G. E., & Haddow, J. E. (1987). Maternal serum α-fetoprotein, age, and
Down syndrome risk. American Journal of Obstetrics and Gynecology, 156(2),
460–463.
Reddy, U. M., & Mennuti, M. T.(2006). Incorporating first-trimester Down syndrome studies into prenatal screening: executive summary of the National Institute of Child Health and Human Development workshop. Obstetrics & Gynecology, 107(1), 167-173.
Rostant, K., Steed, L., & O'Leary, P. (2003). Survey of the knowledge, attitudes and experiences of Western Australian women in relation to prenatal screening and diagnostic procedures. Australian and New Zealand Journal of Obstetrics and Gynaecology, 43(2), 134-138.
Simpson, J. L. (1981). Pregnancies in women with chromosomal abnormalities. In Schulman, J. D.,and Simpson, J. L., (Ed.), Genetic Diseases in Pregnancy (chap. 13). New York: Academic Press.
Scala, I., Granese, B., Sellitto, M., Salome, S., Sammartino A, Pepe, A., Mastroiacovo, P., … Andria, G. (2006). Analysis of seven maternal polymorphisms of genes involved in homocysteine/folate metabolism and risk of Down syndrome offspring. Genetics in Medicine, 8(7), 409-416.
Statham, H., & Green, J. (1993 ). Serum screening for Down’s syndrome: Some women’s experiences. British Medical Journal, 307(6897), 174-176.
Skotko, B. G., Kishnani, P. S., & Capone, G. T. ( 2009 ). Prenatal diagnosis of Down syndrome: How best to deliver the news. American Journal of Medical Genetics Part A, 149A(11 ), 2361-2367.
Shin, M., Besser, L. M., Kucik, J. E., Lu, C., Siffel, C., & Correa, A. (2009). Prevalence of Down syndrome among children and adolescents
in 10 regions of the United States. Pediatrics, 124(6), 1565 -1571.
Sipek, A., Gregor, V., Horacek, J., & Chudobova, M. (2001). Down syndrome in the Czech Republic during 1961-1997 : Prevalence, prenatal diagnosis and maternal-age-specific rates. Journal of Obstetrics & Gynaecology, 21(3), 266-269.
Sonek, J. D., Nicolaides, K. H. (2002). Prenatal ultrasonographic diagnosis of nasal bone abnormalities in three fetuses with Down syndrome. American Journal of Obstetrics & Gynecology, 186(1), 139-141.
Saller, D. N. Jr., & Canick, J. A. (1996). Maternal serum screening for fetal Down syndrome: clinical aspects. Clinical Obstetrics and Gynecology, 39(4), 783-792.
Spencer, K. (1991). Evaluation of an assay of the free beta-subunit of choriogonadotropin and its potential value in screening for Down's syndrome. Clinical Chemistry, 37(6), 809-814.
Spencer, K., & Nicolaides, K.H. (2002). A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A. Prenatal Diagnosis, 22(10), 877-879.
Sonek, J. D., & Nicolaides, K. H. (2002) Prenatal ultrasonographic diagnosis of nasal bone abnormalities in three fetuses with Down syndrome. American Journal of Obstetrics & Gynecology, 186(1), 139-141.
Trachtenberg, F., Dugan, E., & Hall, M. A. (2005). How patients’ trust relates to their involvement in medical care. The Journal of family practice, 54(4), 344-352.
Tam, C., McKenna, K., Goh, Y. I., Klieger-Grossman, C., O'Connor, D. L., Einarson, A, & Koren, G. (2009). Periconceptional folic acid supplementation: a new indication for therapeutic drug monitoring. Therapeutic Drug Monitoring, 31(3), 319-326.
Thistlethwaite, J. E., & Jordan, J. ( 2000). Antenatal screening in the community: The views and experience of women in one general practice. Primary Health Care Research and Development, 1( 1), 29-38.
Valenti, C., Schutta, E. J., & Kehaty, T. (1968). Prenatal diagnosis of Down's syndrome. Lancet, 2(7561), 220.
Van Lith, J. M., Pratt, J. J., Beekhuis, J. R., & Mantingh, A. (1992). Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome. Prenatal Diagnosis. 12(10), 801-806.
West, K. P. Jr., Shamim, A. A., Mehra, S., Labrique, A. B., Ali, H., Shaikh, S., … Christian, P. (2014). Effect of maternal multiple micronutrient vs iron-folic acid supplementation on infant mortality and adverse birth outcomes in rural Bangladesh: the JiVitA-3 randomized trial. The Journal of the American Medical Association, 312(24), 2649-2658.
Wald, N. J., & Hackshaw, A. K. (2000). Advances in antenatal screening for Down syndrome. Baillieres Best Practice & Research: Clinical Obstetrics & Gynaecology, 14(4),563-580.
Wald, N. J., Watt, H. C., & Hackshaw, A. K. (1999). Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. The New England Journal of Medicine, 341(7), 461-467.
Waltz, C. F., Strickland, O. L., & Lenz, E. R. (1991). Measurement in nursing research (2nd ed.). Philadelphia: A. Davis.
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52259-
dc.description.abstract在台灣地區,引起智能障礙最常見的染色體異常疾病就是唐氏症,隨著產前唐氏症檢查技術日新月異,檢查的項目有多種不同的選擇,孕婦應該對於產前遺傳診斷的基本認知有所了解。故在進行產前遺傳檢測時,應對孕婦提供正確且完整資訊之相關知識,使其了解產前遺傳檢查及檢查結果的意義,再行最佳判斷並能夠做出適宜之決定,以減少孕婦的壓力和焦慮,使其更能充分瞭解到相關資訊。
本研究目的在探討懷孕婦女對產前唐氏症篩檢和診斷過程中知識、態度與經驗的相關性研究,研究工具採用在澳洲使用過的公開結構式問卷「產前篩檢和產前診斷的調查」翻譯而成,為提高問卷之可信度,先進行信效度的檢定。自2014年11月1日至2015年4月30日期間,於台北市某區域教學醫院婦產科門診收案。對象為懷孕週數滿20週以上到生產前的孕婦,本研究總計實際回收有效問卷共計207份,回收率96.28%。
研究結果:孕婦的年齡平均34.3歲,為高齡孕婦,在接受產前唐氏症篩檢和診斷的知識量表經標準化之後平均得分為62.77分(滿分為100分),知識程度不是很高,得分欠理想,需有加強之必要。孕婦產前唐氏症篩檢和診斷知識之主要相關因素為:年齡、懷孕次數、生產次數其結果皆達統計上顯著意義。態度量表顯示平均得分為68.92分(滿分為100分),顯示孕婦之態度趨向於正向、積極。經驗量表在第一孕期和第二孕期唐氏症篩檢在大部分的孕婦都有聽說過、醫護人員也都有建議、自己也有瞭解檢驗項目目的,差別在第一孕期自己有做佔多數,第二孕期母血唐氏症篩檢自己並沒有做佔多數;絨毛膜取樣術大部分的孕婦都認為有聽說過但是醫護人員沒有建議、也不瞭解檢驗項目目的、自己也並沒有做;羊膜穿刺術方面在大部分的孕婦都表示有聽說過、醫護人員也都有建議、自己也有瞭解檢驗項目目的但是自己並沒有做。孕婦在產前唐氏症篩檢和診斷達顯著相關的因素為知識與態度,而知識與態度、年齡、懷孕次數及生產次數之間的關係達統計上顯著相關,態度與懷孕次數亦達統計上顯著相關。
本研究結果可為臨床實務、醫護教育、政府政策、孕婦健康手冊產檢相關資訊等方面及臨床醫護人員、遺傳諮詢師等相關人員參考,並能夠給予孕婦最適時的協助,以提高孕婦產前唐氏症篩檢和診斷的相關知識,減少國人對遺傳疾病之恐慌及醫療成本的浪費。
zh_TW
dc.description.abstractIn Taiwan, the most common cause of chromosomal disorder causing mental retardation is Down syndrome. Along with rapid advanced technology of prenatal Down syndrome screening and diagnosis, there are a number of different options of examination. Pregnant women should possess basic knowledge for understanding their prenatal genetic diagnosis. Therefore, during prenatal genetic examinations, women should be provided accurate and complete relevant information to understand the meaning of prenatal genetic examination results, so that while reducing stress and anxiety, the appropriate decisions could be made.
This study aimed to explore the relation between pregnant women’s prenatal Down syndrome screening and diagnosis process knowledge, attitude and experience. A structured questionnaire used in Australia 'prenatal screening and prenatal diagnosis' was translated into Chinese. The reliability and validity were established. Data were collected from November 1st 2014 to April 30th 2015, at maternity clinics in a regional teaching hospital in Taipei. A total of 207 pregnant women over 20 weeks gestation were recruited, the response rate was 96.28%.
The study results showed the average age of pregnant women was 34.3 years old, average prenatal screening and diagnosis of Down syndrome knowledge scale standardized score of 62.77 points, which is not satisfied and should be strengthened. The main factors related to prenatal screening and diagnosis of Down syndrome knowledge including age, number of pregnancies, and the parity. Attitude scale showed an average standardized score of 68.92 points, revealing the attitude of pregnant women tend to be positive and active. As to experience scale, majority of pregnant women have heard the first trimester and the second trimester screening for Down syndrome, also have recommended by health care workers, and have an understanding of the purpose, most of them have done in the first trimester. Most of the pregnant women did not do second trimester maternal serum screening for Down syndrome. Most pregnant women have heard of chorionic villus sampling technique but health care workers did not recommend, do not understand the purpose, and did not do it. Most pregnant women have heard amniocentesis, recommended by health care workers, understanding of the purpose but did not do it. Significant factors of pregnant women’s Down syndrome prenatal screening and diagnostic knowledge and attitude were examined. Age, number of pregnancies, parity were significantly correlated to knowledge. The attitude and the number of pregnancies also significantly statistical correlated.
The results of this study may be useful to clinical practice, nursing education, governmental policy, genetic counselors etc. We suggest that timely information of prenatal Down syndrome screening and diagnosis should be given to most pregnant women, thereby reducing panic effectively to the genetic diseases and related medical costs.
en
dc.description.provenanceMade available in DSpace on 2021-06-15T16:10:28Z (GMT). No. of bitstreams: 1
ntu-104-P01448006-1.pdf: 4521359 bytes, checksum: d94ea2e4fd97b32ae8f5fd181247f88f (MD5)
Previous issue date: 2015
en
dc.description.tableofcontents目 錄
口試委員會審定書…………………………………………………………………..…i
誌謝……………………………………………………………………………….……ii
中文摘要………………………………………………………………………..…… iii
英文摘要………………………………………………………………………………iv
目錄……………………………………………………………………………………vi
圖表目錄…………………………………………………...…………………………vii
附錄…………………………………………………...………………….…………. viii
目錄
第一章 緒論………………………………………………………………....….…... 1
第一節 研究動機及其重要性…………………………………………....….....1
第二節 研究目的………………………………………………………...…......6
第三節 研究問題………………………………………….……………....……7
第四節 名詞界定……………………………………………….…...………….8
第二章 文獻探討…………………………………….………………………......…11
第一節 唐氏症……………………………………………………….…….….11
第二節 產前唐氏症篩檢和遺傳診斷方式之演進………………….……......12
第三節 台灣孕婦產前唐氏症篩檢和遺傳診斷實施之現況…….…..……... 14
第四節 孕婦的產唐氏症篩檢和遺傳診斷知識、態度及經驗之相關研究探
討…………….………………………………………………….….…17

第三章 研究方法…………………………………………………………………...22
第一節 研究架構……………………………………………………………...22
第二節 研究假設……………………………………………………………...24
第三節 研究設計……………………………………………………………...25
第四節 研究對象與場所……………………………………………………...26
第五節 研究工具……………………………………………………………...27
第六節 研究工具效度與信度檢定…………………………………………...32
第七節 資料收集過程………………………………………………………...36
第八節 資料處理與分析……………………………………………………...38
第九節 研究倫理考量………………………………………………………...40
第四章 研究結果…………………………………………………………………...41
第一節 基本資料的描述性分析………………………….……………..........41
第二節 孕婦對產前唐氏症篩檢和診斷的知識、態度與經驗之描述性分析45
第三節 孕婦對產前唐氏症篩檢和診斷的知識、態度與經驗之差異分析.....60
第四節 個人背景變項對產前唐氏症篩檢和診斷的知識、態度之相關分析64
第五章 討論……………………...……………………………..………………......66
第一節 產前唐氏症篩檢和診斷知識分析………………………...……........66
第二節 產前唐氏症篩檢和診斷態度分析……….………….……..………...69
第三節 產前唐氏症篩檢和診斷經驗分析……………...………………...….70
第四節 影響懷孕婦女產前唐氏症篩檢和診斷知識、態度之相關分析…...78

第六章 結論與建議……………………….....………………………..…………....79
第一節 結論……...………………………..………………..………………....79
第二節 建議…………...…………………………………………………........83
第三節 研究限制……………...……………………..……………………......86
參考文獻…………………….....………………………………………………..…....88
中文文獻………………….....……………………………………………..…....88
英文文獻…….....………………………………………...………………..….....91
圖表目錄

圖3-1 概念架構圖………………….………………………………..………..23
圖3-2 二階段收案方式……….....……………………………………..……..28
表3-1 專家效度之平均得分及專家一致性………….....……………..……..34
表3-2 各量表的研究工具之內在一致性信度檢定測試結果……....………..35
表4-1 懷孕婦女基本資料概況分析表…………......…………………..……..43
表4-2 產前唐氏症篩檢和診斷之知識量表答題情形…......……………..…..46
表4-3 產前唐氏症篩檢和診斷之態度……………......…………………..…..49
表4-4 產前唐氏症篩檢和診斷檢驗項目之經驗……......………………..…..52
表4-5-1沒有接受第一孕期母血唐氏症篩檢和胎兒頸部透明帶超音波檢查
的原因.....................................................................................................54
表4-5-2沒有接受第二孕期母血唐氏症篩檢檢查的原因…..…........................54
表4-5-3沒有接受絨毛膜取樣術檢查的原因…......…………............................54
表4-5-4沒有接受羊膜穿刺術檢查的原因……………………......…................55
表4-6-1有接受第一孕期母血唐氏症篩檢和胎兒頸部透明帶超音波檢查的
原因…………………………………….................................................56
表4-6-2有接受第二孕期母血唐氏症篩檢檢查的原因………......…................56
表4-6-3有接受絨毛膜取樣術檢查的原因…………………..………................57
表4-6-4有接受羊膜穿刺術檢查的原因……………..............…………………57
表4-7 其他關於懷孕期間產前唐氏症篩檢和診斷過程的經驗…..............…58
表4-8 個人背景變項與產前唐氏症篩檢和診斷知識之t檢定與單因子變異
數分析………...................……………………..............................……60

表4-9 個人背景變項與產前唐氏症篩檢和診斷態度之t檢定與單因子變異
數分析………………………………………………......................…...62
表4-10 個人背景等相關變項與知識、態度之間的皮爾森相關分析…..........65
表4-11 懷孕婦女其個人基本屬性及孕產經驗與知識、態度研究假設與結
果驗證…….......................……………………………………………65
附錄
附錄一 專家效度名單…………........……………...………..………………..98

附錄二 作者同意翻譯中文使用授權書………………………………...........99
附錄三 建立專家效度問卷………………………………………….…........100
附錄四 內容效度指標「CVI 值」…………………………..………..........108
附錄五 專家度評分表…………………......…..................…….…................109

附錄六 問卷………………………………………………….............…........124
附錄七 匿名問卷研究說明書…………………………..…………….......... 130
附錄八 同意臨床試驗計畫證明書…………………………….………........134
dc.language.isozh-TW
dc.subject經驗zh_TW
dc.subject孕婦zh_TW
dc.subject產前唐氏症檢查zh_TW
dc.subject知識zh_TW
dc.subject態度zh_TW
dc.subjectprenatal Down syndrome examinationen
dc.subjectexperienceen
dc.subjectattitudeen
dc.subjectknowledgeen
dc.subjectpregnant womenen
dc.title孕婦對唐氏症篩檢和遺傳診斷過程中知識、態度和經驗及其相關因素之探討zh_TW
dc.titleFactors Associated with the Knowledge, Attitudes and Experiences of Pregnant Women in Down Syndrome Screening and Genetic Diagnostic Processen
dc.typeThesis
dc.date.schoolyear103-2
dc.description.degree碩士
dc.contributor.oralexamcommittee賀姝霞,楊雅玲
dc.subject.keyword孕婦,產前唐氏症檢查,知識,態度,經驗,zh_TW
dc.subject.keywordpregnant women,prenatal Down syndrome examination,knowledge,attitude,experience,en
dc.relation.page134
dc.rights.note有償授權
dc.date.accepted2015-08-18
dc.contributor.author-college醫學院zh_TW
dc.contributor.author-dept分子醫學研究所zh_TW
顯示於系所單位:分子醫學研究所

文件中的檔案:
檔案 大小格式 
ntu-104-1.pdf
  未授權公開取用
4.42 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved